News Flashes IGR 22-2

Two-year follow-up assessments are inadequate to draw treatment conclusions and these outcomes might not support altering current treatment approaches to open-angle glaucoma

Glaucoma utility index (GUI) as QoL outcomes may not be appropriate as these instruments mostly measure functional disabilities related to deficits in visual acuity and visual fields

The cost differential between the two study arms was not captured by the study investigators

Our knowledge of the relationship between IOP and glaucoma progression is significantly limited by the low sampling rate of IOP in clinical practice (typically three to four times per year)

Algorithms were developed primarily with data from Asian eyes and may not be generalizable to more diverse populations

Over 70% of patients preferred virtual visits in future if given a choice

An improvement in deepening of the upper eyelid sulcus was observed for twelve eyes at one month and sixteen eyes at three months

The follow-up after the switch was also likely too short for a full assessment of DUES changes

Take-home lesson from this analysis is that applying more treatments lowers IOP more and reduces progression more than applying a single treatment

Netarsudil 0.02% is the first commercially available ocular hypotensive eye drop of which EVP decreasing effect was confirmed in POAG or OHT patients

The advent of Netarsudil 0.02% may stimulate investigation of physiology/pharmacology of not only pre-, but also post-Schlemm's canal aqueous pathway

Limoli et al.'s innovative approach to suprachoroidal MSC transplantation is intriguing

The major strengths of this study are the use of washout pressure measurements, the long-term follow-up and its focus on an important, high-risk group

Once the first crucial year after XEN implantation is successfully passed, these eyes continue to do well over the next several years, potentially attesting to the importance of adequate post-operative management

Central VF progression was significantly more common than peripheral VF progression in the DH group

In the absence of inflammation, both the agonist and antagonist produce the same phenotype. While certainly possible, it suggests the possibility of off-target effects

AI may efficiently and more accurately facilitate genomic discovery in glaucoma

Issue 22-2

Change Issue